Table 1.

Interventional case series

Study name	n	Drug and dose	Mean IVIs	Mean f/u	Outcomes
Campochiaro 2008	20 pt	Ranibizumab 0.3 mg (n = 10) or 0.5 mg (n = 10)	3	3 m	At 3 m, median BCVA gain of 17 letters in 0.3 mg group, 14 letters in 0.5 mg group, with 93% and 89% reduction in excess ME at 3 m, respectively
Costa 2007 (IBeVO Study)	7 pt	Bevacizumab 2.0 mg	3	25 w	Mean BCVA (LogMAR) improved from 1.21 to 0.68
	All I				Mean CRT improved from 730 to 260 μm
					No significant adverse events Side effects = SCH and conjunctival hyperemia
Hoeh 2009	27 eyes	Bevacizumab 2.5 mg	4.1	61 w	At last follow up:
					VA (LogMAR) improved from baseline, 0.75+/-0.38, to 0.57+/-0.48
					Mean CRT decreased from 748+/-265 μm to 373+/-224 μm
					33% (n = 9) had no ME recurrence, 30% (n = 8) had no significant response to treatment
Hsu 2007	30 eyes of 29 pt	Bevacizumab 1.25 mg	2.4	18 w	Improvement in Snellen BCVA from 20/394 to 20/187 at 2 m (NB n = 14 treated with IVTA > 3 m previously)
Iturralde 2006	16 eyes of 15 pt	Bevacizumab 1.25 mg	2.8	3 m	BCVA improved from 1.48 at baseline to 1.05 at 1 m, 0.84 at 3 m
					CRT improved from 887 to 372 μm at 1 m
					(NB n = 9 had prior treatment with IVTA)
Kriechbaum 2008	8 eyes	Bevacizumab 1 mg	4.8	6 m	No significant improvement at 6m:mean BCVA improved from 35 letters (20/200) to 47 letters (20/125)
	All NI				CRT reduced from 585 to 489 μm
Moschos 2008	10 eyes	Bevacizumab 1.25 mg	1	3 m	No improvement in mean BCVA at 3 m
					CRT reduced from 642 to 367 μm at 3 m
Pai 2007	9 eyes	Bevacizumab 1.25 mg	1	3 m	No significant improvement in mean BCVA, from baseline LogMAR 1.3 to 1.14 at 3 m Significant reduction in mean CRT from 615 to 252 μm
Pieramici 2008	10 eyes	Ranibizumab 0.3 mg (n = 5) or 0.5 mg (n = 5)	4.5	9 m	Compared to baseline BCVA, ≥ 15 letter improvement was seen in n = 4 at 3 m, and persisted in n = 3 at 9 m
	All NI				Mean reduction in CRT from baseline was 272 μm at 3 m and 119 μm at 9 m
					No effect of dose on outcome No adverse effects, but n = 1 developed severe rebound edema
Pournaras 2008	8 eyes (6 NI, 2 I)	Bevacizumab 1.25 mg	1.75	3.25 m	Mean BCVA (LogMAR) improved from 0.84 to 0.3 at 3 m and CRT improved from 771 to 344 μm
					No adverse events
Prager 2009	8 eyes	Bevacizumab 1 mg to 2.5 mg	8	12 m	BCVA improved by 7 letters (not significant). CRT reduced by 268 μm compared to baseline (P = 0.007)
					2 eyes lost to f/u
Priglinger 2007	46 eyes (30 NI, 16 I)	Bevacizumab 1.25 mg	2.96	6 m	Mean letter gain at 6 m was 13.9
					At baseline vs 6 m, BCVA was < 20/200 in 52% vs 22%, 20/200 to 20/50 in 46% vs 50% and better than 20/50 in n = 1 vs 28%
					CRT declined from 535 μm at baseline to 323 μm at 6 m
					No adverse events
					NB n = 26 had prior treatment with IVTA/RON/ PRP
Rensch 2009	25 eyes All NI	Bevacizumab 1.5 mg	3	6 m	Mean duration of CRVO prior to treatment was 4.2 (sd 3.6) days
					Significant improvement in mean VA(logMAR) from 0.97 (+/-0.40) at baseline to 0.69 +/-0.52 at 6 m (P = 0.015); 56% patients improved by 3 or more lines. Significant reduction in mean CRT from 530+/-152 μmat baseline to 346 +/-129 μm at 6 m (P < 0.001).
Rouvas 2009	12 eyes	Ranibizumab (dose not specified)	7.4	12 m	Mean CRT improved from 480+/-166 μm at baseline to 230 +/-33 μm (P < 0.001) at 12 m. Compared to baseline, n = 8 had >= 15 letter improvement in VA, n = 3 had stable VA and n = 1 had worse VA.
	9 NI, 3 I				None of the n = 9 with NICRVO converted to ischemic CRVO at 12 m
Schaal 2007	18 pt	Bevacizumab 2.5 mg	2.6±1.4	23 w	At last visit 73.3% had ≥ 15 letter improvement on ETDRS
					Mean CRT decreased from 921 μm to 239 μm
					No complications or side effects
Stahl 2007	14 eyes	Bevacizumab 1.25 mg	1	8.9 w	Mean BCVA (LogMAR) improved from 0.58 at baseline to 0.30 at 3 w, 0.31 at 6 w and 0.44 at 9 w
					Mean CRT improved from 585 μm at baseline to 299 μm at 3 w, 424 μm at 6 w and 474 μm at 9 w
					Treatment within 3 m of onset versus later had better visual outcome (P = 0.05)
Wu 2010	44 eyes	Bevacizumab 1.25 mg or 2.5 mg	7.2 (for 1.25 mg group)	24 m	Mean LogMAR BCVA improved significantly by 0.35 +/-0.57 units in the 1.25 mg group*, and 0.27 +/- 0.68 units in the 2.5 mg group*
			8.1 (for 2.5 mg group)		In the 1.25 mg group, 56.8% gained 15 letters or more (ETDRS chart), and 13.6% lost 15 letters or more. CRT improved from 635+/-324 μm at baseline to 264+/-160 μm*
					In the 2.5 mg group, 57.1% gained 15 letters or more (ETDRS chart), and 16.7% lost 15 letters or more. CRT improved from 528+/-213 μm at baseline to 293+/-137 μm*
					* P < 0.0001, compared to baseline
					No statistically significant differences between the different doses were observed

BCVA: best-corrected visual acuity

CRT: central retinal thickness

ETDRS: Early Treatment Diabetic Retinopathy Study

f/u: follow up

I: ischemic (NB - definitions differ by author)

IVIs: intravitreal injections

IVTA: intravitreal triamcinolone

LogMAR: logarithm of minimal angle of resolution

μm: micrometers

m: months

mg: milligram

NI: non-ischemic

pt: patient

PRP: pan-retinal photocoagulation

RON: radical optic neurotomy

SCH: sub-conjunctival hemorrhage

vs: versus

w: weeks